Trevi Therapeutics (TRVI) Aandelenoverzicht
Trevi Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt en commercialiseert een onderzoekstherapie voor de behandeling van chronische hoest bij patiënten met idiopathische longfibrose (IPF) en niet-IPF interstitiële longziekte, en refractaire chronische hoest. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
TRVI Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Trevi Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$17.54 |
| 52 Week Hoogtepunt | US$20.22 |
| 52 Week Laag | US$6.55 |
| Bèta | 1 |
| 1 maand verandering | 0.086% |
| 3 maanden verandering | 21.69% |
| 1 Jaar Verandering | 122.81% |
| 3 jaar verandering | 665.72% |
| 5 jaar verandering | 822.89% |
| Verandering sinds IPO | 122.24% |
Recent nieuws en updates
TRVI: Higher Long Term Profit Margin Assumptions Will Support A Richer Future Multiple
Trevi Therapeutics' analyst price target has been revised from $23.90 to $24.90. Analysts attribute this change to updated assumptions around long term profit margins and P/E expectations as key drivers of the revision.TRVI: Equity Raise And Trial Milestones Will Support A Higher Future Multiple
Analysts have raised their price target on Trevi Therapeutics to $23.90 from $21.64, citing updated views on fair value and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research on Trevi Therapeutics highlights differing views on how the updated price targets align with the company’s execution risks and valuation assumptions.Recent updates
TRVI: Higher Long Term Profit Margin Assumptions Will Support A Richer Future Multiple
Trevi Therapeutics' analyst price target has been revised from $23.90 to $24.90. Analysts attribute this change to updated assumptions around long term profit margins and P/E expectations as key drivers of the revision.TRVI: Equity Raise And Trial Milestones Will Support A Higher Future Multiple
Analysts have raised their price target on Trevi Therapeutics to $23.90 from $21.64, citing updated views on fair value and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research on Trevi Therapeutics highlights differing views on how the updated price targets align with the company’s execution risks and valuation assumptions.Trevi Therapeutics: Late-Stage Transition Meets Execution Risk
Summary Trevi Therapeutics is transitioning to a late-stage biotech, prioritizing Haduvio for IPF-related chronic cough as its lead indication. TRVI's strong cash position, bolstered by a $150M stock offering, funds operations into 2028 and reduces near-term financing risk. Haduvio's Phase 3 trials in IPF chronic cough, with quantifiable endpoints and safety focus, are the pivotal near-term catalysts for TRVI. Despite a premium valuation (P/B 10.2x–16.3x), TRVI's upside relies on successful late-stage execution; I recommend holding until Phase 3 data. Read the full article on Seeking AlphaChronic Cough Trials And Focused Pulmonologist Reach Will Support Long Term Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio for chronic cough conditions associated with fibrotic lung diseases and refractory chronic cough. What are the underlying business or industry changes driving this perspective?
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...Trevi adds 19% on full data set from mid-stage cough study
Clinical-stage biopharma, Trevi Therapeutics, Inc. (NASDAQ:TRVI) gained 19% pre-market Monday after the company announced complete data from its Phase 2 trial for lead asset Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) U.K.-based CANAL study was designed to compare Haduvio, an oral extended-release formulation of pain therapy nalbuphine, against placebo in terms of the mean daytime cough frequency at Day 22 as the primary endpoint, as measured by an objective cough monitor. The full set of subjects (N=38) reached the primary endpoint with statistical significance indicating a 52.5% change in daytime cough frequency for Haduvio compared to placebo (p<0.0001). The reduction of cough frequency stood at ~76.1% and 25.3% in Haduvio and placebo arms, respectively. The safety profile was in line with data from previous studies for the treatment, and two adverse events were found to be unrelated to the experimental therapy. TRVI expects to start the next trial for this indication in H1 2023. A previous readout from 26 patients in the CANAL trial indicated a 52% placebo-adjusted reduction in daytime cough events for Haduvio.Trevi Therapeutics: Moving Forward
Summary Today, we put Busted IPO Trevi Therapeutics in the spotlight for the first time ever. The company's primary drug candidate Haduvio is moving towards late-stage development as a treatment for prurigo nodularis as well as chronic cough in adults with idiopathic pulmonary fibrosis. An investment analysis follows in the paragraphs below. "It's not unpatriotic to denounce an injustice committed on our behalf, perhaps it's the most patriotic thing we can do."― E.A. Bucchianeri Today, we take our first look at Trevi Therapeutics Inc. (TRVI). The small biopharma firm came public just over three years ago and is deep in Busted IPO territory even with a nice rebound in the shares so far in 2022. What lies ahead for Trevi Therapeutics? An analysis follows below. Seeking Alpha Company Overview Trevi Therapeutics is a clinical-stage biopharmaceutical company based out of New Haven, CT. The company focuses on the development of medicines to treat serious neurologically mediated conditions. Its primary asset in development is Haduvio which is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. Haduvio has a dual mechanism of action by acting as both an antagonist (blocker) to the body's mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. March Company Presentation This candidate is currently being evaluating for the treatment of prurigo nodularis or PN and chronic cough in adults with idiopathic pulmonary fibrosis or IPF. Chronic cough represents a significant unmet need for IPF patients, as the majority of these patients report this cough as one of their most bothersome aspects of their disease. March Company Presentation Haduvio or Nalbuphine Extended Release [ER] has also been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. In 2011, Endo Pharmaceuticals partnered with Trevi to develop and market compounds incorporating nalbuphine hydrochloride. The stock currently trades just over three bucks a share and sports an approximate market capitalization of $140 million. Pipeline Developments Company Website The stock got a bump in late June 29th when the company disclosed that Haduvio had met key goals in a Phase 2b/3 'PRISM' study for patients with prurigo nodularis. 25% met the primary efficacy endpoint, a clinical measure called 4-point reduction in the Worst Itch - Numerical Rating Scale compared to just 14% of the placebo group. March Company Presentation Patients are currently completing the one-year open-label extension study, which should be over in January. The company is in the process of having an end of Phase 2 meeting with the FDA to discuss the data, next steps and the design for a registrational study that could lead to approval dependent on results. The company would like to do a six-month study with three treatment groups. March Company Presentation Four months before, interim data from a Phase 2 trial evaluating Haduvio to treat IPF suffering from chronic cough found a 52% placebo-adjusted reduction in daytime cough events and the compound was well tolerated. Full results should be out by the end of this quarter. A meeting with the FDA should happen to soon to move this effort to the next stage of development. The company believes this will begin in the first half of 2023. Haduvio could have other potential indications in this category (see above) for other indications. March Company Presentation Analyst Commentary & Balance Sheet Aegis Capital, Oppenheimer and Needham have all reiterated Buy ratings on TRVI over the past four months. All have identical $10 price targets on the stock.Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rendement voor aandeelhouders
| TRVI | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -8.0% | 1.8% | -1.1% |
| 1Y | 122.8% | 42.8% | 15.1% |
Rendement versus industrie: TRVI overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 42.8 % opleverde.
Rendement versus markt: TRVI overtrof de US markt, die het afgelopen jaar een rendement opleverde van 15.1 %.
Prijsvolatiliteit
| TRVI volatility | |
|---|---|
| TRVI Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: TRVI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van TRVI is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2011 | 34 | Jennifer Good | www.trevitherapeutics.com |
Trevi Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt en commercialiseert onderzoekstherapieën voor de behandeling van chronische hoest bij patiënten met idiopathische longfibrose (IPF) en niet-IPF interstitiële longziekte, en refractaire chronische hoest. Het bedrijf ontwikkelt Haduvio, een orale formulering met verlengde afgifte van nalbuphine, die zich in fase 2b van de klinische studie Cough Reduction in IPF with nalbuphine ER bevindt voor de behandeling van chronische hoest bij patiënten met IPF, en in fase 2a van de klinische studie bij patiënten met refractaire chronische hoest. Trevi Therapeutics, Inc. heeft een licentieovereenkomst met Keenova Therapeutics plc voor de ontwikkeling en commercialisering van producten die nalbuphine hydrochloride bevatten in verschillende formuleringen.
Trevi Therapeutics, Inc. Samenvatting
| TRVI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.44b |
| Inkomsten(TTM) | -US$45.61m |
| Inkomsten(TTM) | n/a |
Is TRVI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TRVI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$45.61m |
| Inkomsten | -US$45.61m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.32 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde TRVI op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/24 22:37 |
| Aandelenkoers aan het einde van de dag | 2026/07/24 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Trevi Therapeutics, Inc. wordt gevolgd door 16 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Conor MacKay | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |